ReviewJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2018
Scientific Advances and New Frontiers in Mesothelioma Therapeutics.
Review in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 112 citations in OpenAlex.
- Malignant mesothelioma of the tunica vaginalis testis initially misdiagnosed as a benign testicular hydrocele: a case report.Frontiers in oncology · 2026Article
- Malignant mesothelioma of the tunica vaginalis: A case report and comprehensive literature review.Urology case reports · 2026Article
- Comprehensive analysis reveals prognostic gene set that could impacts the response to chemotherapy and immunotherapy outcomes in malignant pleural mesothelioma.Clinical and experimental medicine · 2025Article
- Inhibition of YB-1 phosphorylation enhances cisplatin activity and disrupts cell division in pleural mesothelioma.British journal of cancer · 2025Article
- Review
- Exploring the Anticancer Potential of NO-Donor Oxadiazole Assemblies Against Malignant Pleural Mesothelioma.Pharmaceutics · 2025Article
- Epidemiology and clinical characteristics of mesothelioma in the Chinese population: a multicenter study.Therapeutic advances in medical oncology · 2025Article
- Thonzonium bromide inhibits progression of malignant pleural mesothelioma through regulation of ERK1/2 and p38 pathways and mitochondrial uncoupling.Cancer cell international · 2024Article
- Global burden of mesothelioma attributable to occupational asbestos exposure in 204 countries and territories: 1990-2019.Journal of cancer research and clinical oncology · 2024Article
- Antipodoplanin antibody enhances the antitumor effects of CTLA-4 blockade against malignant mesothelioma by natural killer cells.Cancer science · 2024Article
- Review
- First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis.Orphanet journal of rare diseases · 2023Article
- REDCap and the National Mesothelioma Virtual Bank-a scalable and sustainable model for rare disease biorepositories.Journal of the American Medical Informatics Association : JAMIA · 2023Article
- Chinese expert consensus on the diagnosis and treatment of malignant pleural mesothelioma.Thoracic cancer · 2023Article
- Individualized prediction of survival benefit from postoperative radiotherapy for patients with malignant pleural mesothelioma.Cancer medicine · 2023Article
- Modern Malignant Mesothelioma Manifestation.Cureus · 2023Article
- BAP1 is a novel regulator of HIF-1α.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Coexistence of a novel STRN-ALK, NBEA-ALK double-fusion in an ovarian malignant mesothelioma patient: a case report and review.Frontiers in oncology · 2023Article
- An Examination of the Anti-Cancer Properties of Plant Cannabinoids in Preclinical Models of Mesothelioma.Cancers · 2022Article
- Medical and Surgical Care of Patients With Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2022Review
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 12 institutions in 5 countries.
Funding
Abstract
Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer that arises from the mesothelial surface of the pleural and peritoneal cavities, the pericardium, and rarely, the tunica vaginalis. The incidence of MPM is expected to increase worldwide in the next two decades. However, even with the use of multimodality treatment, MPM remains challenging to treat, with a 5-year survival rate of less than 5%. The International Association for the Study of Lung Cancer has gathered experts in different areas of mesothelioma research and management to summarize the most significant scientific advances and new frontiers related to mesothelioma therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.